[go: up one dir, main page]

WO2004070008A8 - Techniques et compositions d'utilisation de suramine, de polysulfate pentosane, d'antisens de telomerase et d'inhibiteurs de la telomerase - Google Patents

Techniques et compositions d'utilisation de suramine, de polysulfate pentosane, d'antisens de telomerase et d'inhibiteurs de la telomerase

Info

Publication number
WO2004070008A8
WO2004070008A8 PCT/US2004/002609 US2004002609W WO2004070008A8 WO 2004070008 A8 WO2004070008 A8 WO 2004070008A8 US 2004002609 W US2004002609 W US 2004002609W WO 2004070008 A8 WO2004070008 A8 WO 2004070008A8
Authority
WO
WIPO (PCT)
Prior art keywords
telomerase
compositions
methods
suramin
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/002609
Other languages
English (en)
Other versions
WO2004070008A2 (fr
WO2004070008A3 (fr
Inventor
Jessie L-S Au
M Guillaume Wientjes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2006503176A priority Critical patent/JP2007525414A/ja
Priority to AU2004209428A priority patent/AU2004209428A1/en
Priority to CA002515000A priority patent/CA2515000A1/fr
Priority to EP04706977A priority patent/EP1606302A4/fr
Publication of WO2004070008A2 publication Critical patent/WO2004070008A2/fr
Publication of WO2004070008A3 publication Critical patent/WO2004070008A3/fr
Priority to US11/193,883 priority patent/US20050282893A1/en
Anticipated expiration legal-status Critical
Publication of WO2004070008A8 publication Critical patent/WO2004070008A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des techniques et des compositions permettant d'inhiber l'activité télomérase et un traitement de maladies ou d'états induits par la télomérase. Ces techniques, ces composés et ces compositions peuvent être utilisés seuls ou en combinaison avec d'autres agents pharmaceutiquement actifs, une intervention chirurgicale ou un traitement par rayons pour traiter des états ou des maladies induites par l'activité télomérase, par exemple pour traiter un cancer.
PCT/US2004/002609 2003-01-31 2004-01-30 Techniques et compositions d'utilisation de suramine, de polysulfate pentosane, d'antisens de telomerase et d'inhibiteurs de la telomerase Ceased WO2004070008A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2006503176A JP2007525414A (ja) 2003-01-31 2004-01-30 スラミン、ペントサン・ポリサルフェート、テロメラーゼアンチセンス、及びテロメラーゼ阻害剤を用いるための方法及び成分
AU2004209428A AU2004209428A1 (en) 2003-01-31 2004-01-30 Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CA002515000A CA2515000A1 (fr) 2003-01-31 2004-01-30 Techniques et compositions d'utilisation de suramine, de polysulfate pentosane, d'antisens de telomerase et d'inhibiteurs de la telomerase
EP04706977A EP1606302A4 (fr) 2003-01-31 2004-01-30 Techniques et compositions d'utilisation de suramine, de polysulfate pentosane, d'antisens de telomerase et d'inhibiteurs de la telomerase
US11/193,883 US20050282893A1 (en) 2004-01-30 2005-07-29 Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44406103P 2003-01-31 2003-01-31
US60/444,061 2003-01-31

Publications (3)

Publication Number Publication Date
WO2004070008A2 WO2004070008A2 (fr) 2004-08-19
WO2004070008A3 WO2004070008A3 (fr) 2005-05-26
WO2004070008A8 true WO2004070008A8 (fr) 2005-09-29

Family

ID=32850822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/002609 Ceased WO2004070008A2 (fr) 2003-01-31 2004-01-30 Techniques et compositions d'utilisation de suramine, de polysulfate pentosane, d'antisens de telomerase et d'inhibiteurs de la telomerase

Country Status (6)

Country Link
EP (1) EP1606302A4 (fr)
JP (1) JP2007525414A (fr)
CN (1) CN1768075A (fr)
AU (1) AU2004209428A1 (fr)
CA (1) CA2515000A1 (fr)
WO (1) WO2004070008A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3646876T3 (fi) * 2012-12-07 2024-05-14 Geron Corp Telomeraasinestäjä imetelstaatti myeloproliferatiivisten sairauksien ja myeloproliferatiivisten kasvainten hoitoa varten
RU2019121873A (ru) 2016-12-13 2021-01-15 БЕТА ТЕРАПЬЮТИКС ПиТиУай ЛТД Ингибиторы гепараназы и их применение
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
WO2018107226A1 (fr) * 2016-12-13 2018-06-21 Beta Therapeutics Pty. Ltd. Méthodes de traitement de troubles oculaires
JPWO2022114111A1 (fr) * 2020-11-27 2022-06-02
CN119770468B (zh) * 2025-01-03 2025-10-31 中国人民解放军军事科学院军事医学研究院 苏拉明钠在预防和/或治疗放射性肠损伤中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882893A (en) * 1997-12-04 1999-03-16 Millennium Pharmaceuticals, Inc. Nucleic acids encoding muscarinic receptors and uses therefor

Also Published As

Publication number Publication date
AU2004209428A1 (en) 2004-08-19
EP1606302A4 (fr) 2009-02-18
CN1768075A (zh) 2006-05-03
WO2004070008A2 (fr) 2004-08-19
WO2004070008A3 (fr) 2005-05-26
EP1606302A2 (fr) 2005-12-21
JP2007525414A (ja) 2007-09-06
CA2515000A1 (fr) 2004-08-19

Similar Documents

Publication Publication Date Title
WO2007087068A3 (fr) Inhibiteurs de tyrosine kinase et leurs utilisations
WO2008089307A3 (fr) Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer
WO2006091395A3 (fr) Inhibiteurs d'activite d'akt
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
WO2006135627A3 (fr) Inhibiteurs de l'activite akt
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
WO2008039218A3 (fr) Inhibiteurs de la tyrosine kinase de bruton
WO2007130383A3 (fr) Compositions et traitements utilisant des pyridazines et des secrétases
WO2007064872A3 (fr) Composes de l'uree utilises dans le traitement du cancer
WO2008011392A3 (fr) Antagonistes ccr1 de proline urée utilisés pour des maladies auto-immunes et l'inflammation
WO2006031806A3 (fr) 2-thiopyrimidinones utilises en tant qu'agents therapeutiques
WO2005079143A3 (fr) Formulations topiques pour le traitement d'etats dermatologiques
WO2004009610A3 (fr) Utilisation de composes nucleosidiques pour la suppression non-sens et le traitement de maladies genetiques
WO2008049856A3 (fr) Procédés pour le traitement de la douleur
WO2006113498A3 (fr) 2-amino-quinazolin-5-ones
WO2007146335A3 (fr) Composés et compositions pour le traitement du cancer
WO2009009417A3 (fr) Compositions pharmaceutiques et procédés pour prévenir, traiter ou inhiber des maladies, des troubles ou des affections inflammatoires cutanés et des maladies, des troubles ou des affections associés à un appauvrissement en collagène
WO2006063350A3 (fr) Compositions et methodes destinees a traiter des affections de l'ongle
WO2006110638A3 (fr) Inhibiteur de l'activite akt
WO2005000192A3 (fr) Inhibiteurs de la glycogene synthase kinase-3
WO2007130501A3 (fr) Polythérapie pour traiter le cancer
WO2006086693A3 (fr) Dispositifs medicaux
WO2007016338A3 (fr) Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer
WO2004070008A3 (fr) Techniques et compositions d'utilisation de suramine, de polysulfate pentosane, d'antisens de telomerase et d'inhibiteurs de la telomerase
WO2007041614A3 (fr) Inhibiteurs de vegf a action prolongee et leurs methodes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 11193883

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 170013

Country of ref document: IL

Ref document number: 2006503176

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2515000

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004706977

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004209428

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004209428

Country of ref document: AU

Date of ref document: 20040130

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004209428

Country of ref document: AU

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 34/2004 UNDER (71,72) THE NAME SHOULD READ "WIENTJES, M. GUILLAUME"

WWE Wipo information: entry into national phase

Ref document number: 20048091217

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004706977

Country of ref document: EP